Dr.Sneha Batra
This retrospective analysis was done after intravitreal injection of 0.7mg Dexamethasone implant (Ozurdex) in 35 eyes of 34 patients with persistent macular edema due to retinal vascular diseases from April 2015 to October 2016. BCVA, Intraocular pressure (IOP) and Central Macular Thickness were noted at baseline (M0) and repeated after one month, three months, four months, and six months post injection.
Results: The average thickness of the retina at baseline was 652µ, the median BCVA was 0.8 logMAR, and corrected IOP was 12.8 mmHg. The maximum decrease in mean retinal thickness was observed at four weeks following the treatment and was 298µ, and visual acuity improved by an average of four lines and was 0.4 logMAR. The only complications observed during the follow-up were transient rise in IOP and progression of cataract.
To conclude, intravitreal Dexamethasone implant is effective in management of persistent macular edema due to retinal vascular disease with optimum safety level.
Leave a Comment